R. Katherine Hyde

This study shows that CBFB::MYH11 is required for leukemia survival in spleen and peripheral blood but not in bone marrow, where it can be bypassed.

This paper establishes patient-derived models of neuroendocrine prostate cancer (NEPC) from metastases, showing they retain tumor heterogeneity and can model metastatic progression.

This paper shows PAMD-Ch17, a modified Plerixafor analog, kills T-ALL cells via mitochondrial dysfunction independent of CXCR4 inhibition.

The paper identifies PTBP1 as a RUNX1 interacting partner required for leukemia cell survival through metabolic gene regulation.

The paper identifies FBXO21 as a therapeutic target in AML by developing a small molecule that inhibits p85 ubiquitination, reducing PI3K pathway activity and inducing cell death.